Safety of JAK inhibitors versus other biologic therapies following anti-TNF failure in patients with rheumatoid arthritis.

ABSTRACT:

Background

Treatment of rheumatoid arthritis (RA) frequently requires Janus kinase inhibitors (JAKi) and biologic DMARDs (bDMARDs) with other mechanisms of action (OMA) after tumour necrosis factor inhibitors (TNFi) failure. Comparative safety data between JAKis and OMA in TNFi-inadequate responders (TNFi-IR) remain limited.

Objectives

To evaluate and compare safety profiles of JAKis versus OMA in TNFi-IR RA patients.

Methods

A retrospective cohort study followed 305 RA patients (163 JAKis; 142 OMA) previously treated with TNFi for up to 24 months. Incidence rates (IR) of adverse events (AEs) per 100 patient-years (PY) and incidence rate ratios (IRR) adjusted for disease activity and previous bDMARD exposure were calculated using Poisson regression.

Results

At

SUBMITTER: Luozzo LD 

PROVIDER: S-EPMC12717725 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature